IDEAS home Printed from https://ideas.repec.org/r/sae/medema/v3y1983i4p419-458.html
   My bibliography  Save this item

The Markov Process in Medical Prognosis

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Visalakshi Jeyaseelan & Tunny Sebastian & Jeyaseelan Lakshmanan & Shrikant I Bangdiwala, 2016. "Longitudinal data analysis of mean passage time among malnutrition states: an application of Markov chains," Journal of Applied Statistics, Taylor & Francis Journals, vol. 43(15), pages 2729-2739, November.
  2. Bruce A. Craig & Peter P. Sendi, 2002. "Estimation of the transition matrix of a discrete‐time Markov chain," Health Economics, John Wiley & Sons, Ltd., vol. 11(1), pages 33-42, January.
  3. Rowan Iskandar, 2018. "A theoretical foundation for state-transition cohort models in health decision analysis," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-11, December.
  4. Xudong Du & Mier Li & Ping Zhu & Ju Wang & Lisha Hou & Jijie Li & Hongdao Meng & Muke Zhou & Cairong Zhu, 2018. "Comparison of the flexible parametric survival model and Cox model in estimating Markov transition probabilities using real-world data," PLOS ONE, Public Library of Science, vol. 13(8), pages 1-13, August.
  5. Felicitas Kuehne & Ursula Rochau & Noman Paracha & Jennifer M. Yeh & Eduardo Sabate & Uwe Siebert, 2022. "Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic Modeling," Medical Decision Making, , vol. 42(2), pages 194-207, February.
  6. Franck Maunoury & Christian Farinetto & Stéphane Ruckly & Jeremy Guenezan & Jean-Christophe Lucet & Alain Lepape & Julien Pascal & Bertrand Souweine & Olivier Mimoz & Jean-François Timsit, 2018. "Cost-effectiveness analysis of chlorhexidine-alcohol versus povidone iodine-alcohol solution in the prevention of intravascular-catheter-related bloodstream infections in France," PLOS ONE, Public Library of Science, vol. 13(5), pages 1-16, May.
  7. Uwe Siebert & Gaby Sroczynski & Jürgen Wasem & Wolfgang Greiner & Ulrike Ravens-Sieberer & Pamela Aidelsburger & Bärbel Kurth & Monika Bullinger & J.-Matthias Schulenburg & John Wong & Siegbert Rossol, 2005. "Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(2), pages 112-123, June.
  8. Gerardo Machnicki & Jean-Francois Ricci & Daniel Brennan & Mark Schnitzler, 2008. "Economic Impact and Long-Term Graft Outcomes of Mycophenolate Mofetil Dosage Modifications Following Gastrointestinal Complications in Renal Transplant Recipients," PharmacoEconomics, Springer, vol. 26(11), pages 951-967, November.
  9. Paul J. Roach & Craig Fleming & Michael D. Hagen & Stephen G. Pauker, 1988. "Prostatic Cancer in a Patient with Asymptomatic HIV Infection," Medical Decision Making, , vol. 8(2), pages 132-144, June.
  10. Dennis A. Plante & Seymour Zimbler & Stephen G. Pauker, 1984. "A Ten-Year-Old Boy with Cerebral Palsy and Femoral Anteversion," Medical Decision Making, , vol. 4(2), pages 229-247, June.
  11. Craig Fleming & John B. Wong & Alan J. Moskowitz & Stephen G. Pauker, 1988. "A Peripartum Neurologic Event: Shooting from the Hip," Medical Decision Making, , vol. 8(1), pages 55-71, February.
  12. Karina Hansen & Christophe Lançon & Mondher Toumi, 2006. "Pharmacoeconomic modelling in schizophrenia," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(1), pages 19-29, March.
  13. C. Kent Kwoh & J. Robert Beck & Stephen G. Pauker, 1984. "Repeated Syncope with Negative Diagnostic Evaluation," Medical Decision Making, , vol. 4(3), pages 351-377, August.
  14. Manouchehr Tavakoli & Neil Pumford & Mark Woodward & Alex Doney & John Chalmers & Stephen MacMahon & Ronald MacWalter, 2009. "An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(1), pages 111-119, February.
  15. Gordon B. Hazen, 2022. "Augmenting Markov Cohort Analysis to Compute (Co)Variances: Implications for Strength of Cost-Effectiveness," INFORMS Journal on Computing, INFORMS, vol. 34(6), pages 3170-3180, November.
  16. Steven M. Shechter & Matthew D. Bailey & Andrew J. Schaefer & Mark S. Roberts, 2008. "The Optimal Time to Initiate HIV Therapy Under Ordered Health States," Operations Research, INFORMS, vol. 56(1), pages 20-33, February.
  17. Simon Frey & Roland Linder & Georg Juckel & Tom Stargardt, 2014. "Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(2), pages 133-142, March.
  18. Uwe Siebert, 2003. "When should decision-analytic modeling be used in the economic evaluation of health care?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 4(3), pages 143-150, September.
  19. Aslam Anis & Huiying Sun & Sonia Singh & John Woolcott & Bohdan Nosyk & Marc Brisson, 2006. "A Cost-Utility Analysis of Losartan versus Atenolol in the Treatment of Hypertension with Left Ventricular Hypertrophy," PharmacoEconomics, Springer, vol. 24(4), pages 387-400, April.
  20. Roy Lothan & Noa Gutman & Dan Yamin, 2022. "Country versus pharmaceutical company interests for hepatitis C treatment," Health Care Management Science, Springer, vol. 25(4), pages 725-749, December.
  21. Adebiyi Sulaimon Olanrewaju & Oyatoye Emmanuel Olateju & Mojekwu Joseph Nnamdi, 2015. "Predicting Customer Churn and Retention Rates in Nigeria’s Mobile Telecommunication Industry Using Markov Chain Modelling," Acta Universitatis Sapientiae, Economics and Business, Sciendo, vol. 3(1), pages 67-80, December.
  22. Franck Maunoury & Anastasiia Motrunich & Maria Palka-Santini & Stéphanie F Bernatchez & Stéphane Ruckly & Jean-François Timsit, 2015. "Cost-Effectiveness Analysis of a Transparent Antimicrobial Dressing for Managing Central Venous and Arterial Catheters in Intensive Care Units," PLOS ONE, Public Library of Science, vol. 10(6), pages 1-14, June.
  23. Beate Jahn & Sarah Friedrich & Joachim Behnke & Joachim Engel & Ursula Garczarek & Ralf Münnich & Markus Pauly & Adalbert Wilhelm & Olaf Wolkenhauer & Markus Zwick & Uwe Siebert & Tim Friede, 2022. "On the role of data, statistics and decisions in a pandemic," AStA Advances in Statistical Analysis, Springer;German Statistical Society, vol. 106(3), pages 349-382, September.
  24. Dominique Bureau & Geneviève Plu-Bureau & Jean-Christophe Thalabard, 1993. "L'évaluation économique des traitements médicaux : méthodes et enjeux," Économie et Statistique, Programme National Persée, vol. 266(1), pages 65-75.
  25. John B. Wong & Robert K. Webb & Stephen G. Pauker, 1987. "Double Trouble," Medical Decision Making, , vol. 7(3), pages 174-193, August.
  26. Donna M. Edwards & Ross D. Shachter & Douglas K. Owens, 1998. "A Dynamic HIV-Transmission Model for Evaluating the Costs and Benefits of Vaccine Programs," Interfaces, INFORMS, vol. 28(3), pages 144-166, June.
  27. David G. Simon, 1986. "A Cost-effectiveness Analysis of Cyclosporine in Cadaveric Kidney Transplantation," Medical Decision Making, , vol. 6(4), pages 199-207, December.
  28. Lukas J.A. Stalpers & Hans J.M. Van Gasteren & Willem A.J. Van Daal, 1989. "DEALE-ing with Life Expectancy and Mortality Rates," Medical Decision Making, , vol. 9(2), pages 150-152, June.
  29. de Wit, G.Ardine & Ramsteijn, Paul G & de Charro, Frank Th, 1998. "Economic evaluation of end stage renal disease treatment," Health Policy, Elsevier, vol. 44(3), pages 215-232, June.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.